ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0409

Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis

Julia Harris1, Leslie Favier2, Emily Fox3, Jordan Jones2, Michael Holland3, Cara Hoffart2, Maria Ibarra3 and Ashley Cooper2, 1Children's Mercy Kansas City, Overland Park, KS, 2Children's Mercy Kansas City, Kansas City, MO, 3Children's Mercy Hospital, Kansas City, MO

Meeting: ACR Convergence 2025

Keywords: Disease Activity, Juvenile idiopathic arthritis, Patient reported outcomes, Quality Indicators

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0387–0429) Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Outcome assessment is essential to optimize care for patients with juvenile idiopathic arthritis (JIA). Although disease activity and patient-reported outcomes (PROs) are different measures, patients commonly report pain and suboptimal overall wellbeing with no active arthritis on exam. We also note the converse with patients denying pain or suboptimal wellbeing with active disease being noted on physical exam. Therefore, in order to ascertain this and determine appropriate future interventions, the objective of this study was to assess for concordance between disease activity outcomes and PROs in patients with non-systemic JIA.

Methods: Data was assessed from January to August 2024. Patients with systemic JIA were excluded. Disease activity outcomes include the 10-joint clinical Juvenile Arthritis Disease Activity Score (cJADAS10), active joint count, and physician global assessment of disease activity (PhGA) value (0-10; 0=no disease activity). PROs include the Childhood Health Assessment Questionnaire (CHAQ) (0-3; 0 is optimal), arthritis-related pain intensity score (0-10; no or mild pain ≤3), and patient/parent global assessment of overall wellbeing (PtGA) (0-10; low value if ≤2).

Results: Data from 584 patients across 1149 visits were analyzed. Active arthritis was present at 31.2% of visits with a mean joint count of 1.19 (Table 1). Mean cJADAS10 was 3.5 (range 1.15 [in patients with inactive arthritis and PhGA=0] to 8.53 [in patients with active arthritis]). Mean PhGA was 0.82, and this value increased to 2.43 for those with active arthritis. Mean PROs were all lower in those with inactive arthritis although ranges remained the same. For those with no active arthritis, 34.4% had functional limitations, 37.5% had pain, and 19.4% had a moderate-high PtGA (Table 2). Conversely, for those with active arthritis, 29.5% reported no pain, 37.5% reported a CHAQ of 0, and 22.8% reported PtGA of 0.

Conclusion: For a considerable percent of patients with JIA with inactive arthritis, there are reports of pain, functional limitations, and suboptimal overall wellbeing. Additionally, many patients with JIA and active arthritis report no pain and optimal wellbeing, which suggests that PROs may be misleading if taken in isolation and physical assessment of arthritis is still paramount to determine active disease. Limitations include not stratifying data by JIA subtype, disease duration, uveitis status, medication use, and/or other comorbidities such as chronic pain syndromes. Continued self-management support is imperative to address factors impacting patient wellbeing. Further studies are needed to determine why this discordance exists and to assess demographic and disease characteristics associated with the discordance between disease activity and PROs.

Supporting image 1Table 1. Disease activity and patient-reported outcome values.

Supporting image 2Table 2. Proportion of patients with disease activity and patient-reported outcome cut-offs based on the presence or absence of active arthritis.


Disclosures: J. Harris: None; L. Favier: None; E. Fox: Pfizer, 2; J. Jones: Pfizer, 2; M. Holland: None; C. Hoffart: None; M. Ibarra: None; A. Cooper: None.

To cite this abstract in AMA style:

Harris J, Favier L, Fox E, Jones J, Holland M, Hoffart C, Ibarra M, Cooper A. Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/discordance-between-disease-activity-and-patient-reported-outcomes-in-patients-with-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/discordance-between-disease-activity-and-patient-reported-outcomes-in-patients-with-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology